Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) EBT (2020 - 2022)

Historic EBT for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q4 2022 value amounting to -$34.3 million.

  • Atea Pharmaceuticals' EBT fell 12829.95% to -$34.3 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$119.5 million, marking a year-over-year decrease of 18622.48%. This contributed to the annual value of -$167.5 million for FY2024, which is 2410.14% down from last year.
  • As of Q4 2022, Atea Pharmaceuticals' EBT stood at -$34.3 million, which was down 12829.95% from -$11.9 million recorded in Q3 2022.
  • Atea Pharmaceuticals' 5-year EBT high stood at $121.2 million for Q4 2021, and its period low was -$42.1 million during Q1 2022.
  • Over the past 3 years, Atea Pharmaceuticals' median EBT value was -$11.9 million (recorded in 2022), while the average stood at $1.1 million.
  • As far as peak fluctuations go, Atea Pharmaceuticals' EBT surged by 48690.94% in 2021, and later crashed by 45719.19% in 2022.
  • Over the past 3 years, Atea Pharmaceuticals' EBT (Quarter) stood at $20.7 million in 2020, then skyrocketed by 486.91% to $121.2 million in 2021, then plummeted by 128.3% to -$34.3 million in 2022.
  • Its EBT was -$34.3 million in Q4 2022, compared to -$11.9 million in Q3 2022 and -$31.2 million in Q2 2022.